The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jeff Hung - Morgan Stanley - Analyst
: Great. You talk about the differences over time and I don't know if you knew this, but actually when I started on the sell side 15 years
ago, Neurocrine was one of the companies that I helped cover. So it has changed quite a bit. But before we dive into the different
programs, maybe a couple of questions for Kevin and Kyle, and Kevin says he's trying to find some time to step away from the CEO
role, but we know he can't get enough of it, and certainly done an amazing job. So Kevin, over your tenure as Neurocrine CEO, what
are you most proud of?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 04, 2024 / 7:20PM, NBIX.OQ - Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare
Conference
And Kyle, what are you most excited about for the future of Neurocrine?
Question: Jeff Hung - Morgan Stanley - Analyst
: Great. Well, let's start with your M4 program. The question everyone wants to ask, given the lack of dose response, what gives you
confidence in 568 and especially at the 20-milligram dose?
Question: Jeff Hung - Morgan Stanley - Analyst
: Just to clarify on the dosing, though, because one question that's come up a lot is, you talked about 20 on the lower end. But I guess
for the study, why didn't look at even one more dose lower?
Question: Jeff Hung - Morgan Stanley - Analyst
: And given the placebo-adjusted reduction in PANSS, and the effect size are lower than the earlier KarXT or amaracladine studies.
Can you just talk about what gives you confidence that 568 will be better than the others?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 04, 2024 / 7:20PM, NBIX.OQ - Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare
Conference
Question: Jeff Hung - Morgan Stanley - Analyst
: And you mentioned that you have highest conviction in 568 amongst your muscarinic candidates. So how do you think about the
prioritization of indications across M4 versus M1/M4 mechanism. I'll let Kyle talk about this.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 04, 2024 / 7:20PM, NBIX.OQ - Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare
Conference
Question: Jeff Hung - Morgan Stanley - Analyst
: Great. The company said that 986 is a better version of our (inaudible) some tolerability issues and impacts cognition. So what gives
you confidence in this target in 986?
Question: Jeff Hung - Morgan Stanley - Analyst
: Great. Well, less than one minute left. Last question. I'll just open for you say whatever you'd like. I think this -- anything you want to
say to the street.
Question: Jeff Hung - Morgan Stanley - Analyst
: Looks like we'll leave it there. Thanks so much for your time.
| 
